A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

NCT02624986 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.

Conditions

Interventions

Sponsor

Hoffmann-La Roche